Xing-Xing He (Xingxing He)

ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 8

Top Venues

Signal transduction and targeted therapy

Journal of experimental & clinical cancer research : CR

Experimental hematology & oncology

Cancer medicine

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology Nov 01 2015

China

associate professor :: Institute of Liver and Gastrointestinal Diseases

Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology Jul 01 2010 - Oct 31 2015

China

research associate :: Institute of Liver Diseases

Education History

Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology

China

PHD :: Department of Gastroenterology

Hubei University Of Science and Technology

China

BSC :: Department of Clinical Medicine

Publications

Yuan Yuan, Peiyuan Li, Jianghui Li, Zhao Qiu, Ying Chang, Xing-Xing He
Protein lipidation in health and disease: molecular basis, physiological function and pathological implication. Signal transduction and targeted therapy 9 (1) (2024)
Yuan Yuan, Peiyuan Li, Jianghui Li, Zhao Qiu, Ying Chang, Xing-Xing He
Protein lipidation in health and disease: molecular basis, physiological function and pathological implication. Signal transduction and targeted therapy 9 (1) (2024)
Yuan Yuan, Peiyuan Li, Jianghui Li, Zhao Qiu, Ying Chang, Xing-Xing He
Protein lipidation in health and disease: molecular basis, physiological function and pathological implication. Signal transduction and targeted therapy 9 (1) (2024)
Xiangyuan Luo, Mengdie Cao, Fan Gao, Xing-Xing He
YTHDF1 promotes hepatocellular carcinoma progression via activating PI3K/AKT/mTOR signaling pathway and inducing epithelial-mesenchymal transition. Experimental hematology & oncology 10 (1) (2021)
Xiang-Yuan Luo, Kong-Ming Wu, Xing-Xing He
Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets. Journal of experimental & clinical cancer research : CR 40 (1) (2021)
Mengdie Cao, Xiangyuan Luo, Kongming Wu, Xing-Xing He
Targeting lysosomes in human disease: from basic research to clinical applications. Signal transduction and targeted therapy 6 (1) (2021)
Lian Liu, Jia-Qi Sheng, Mu-Ru Wang, Yun Gan, Xiao-Li Wu, Jia-Zhi Liao, De-An Tian, Xing-Xing He, Pei Yuan Li
Primary Cilia Blockage Promotes the Malignant Behaviors of Hepatocellular Carcinoma via Induction of Autophagy. BioMed research international 2019 (2019)
Fei Xu, Jia-Zhi Liao, Guang-Ya Xiang, Peng-Xuan Zhao, Feng Ye, Qiu Zhao, Xing-Xing He
MiR-101 and doxorubicin codelivered by liposomes suppressing malignant properties of hepatocellular carcinoma. Cancer medicine 6 (3) (2017)

Xing-Xing He.css-eqlu8i{font-size:small;padding-left:4px;} (Xingxing He)

Publication Activity (10 Years)

Top Topics

Top Venues

Xing-Xing He (Xingxing He)